ASCO recommends osimertinib consolidation for patients with unresectable, stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation who have completed chemoradiation.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...